Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From The Witness Daily

Mother Russia: South Florida sees a boom in 'birth tourism'

Mar 22, 2019

MIAMI — Every year, hundreds of pregnant Russian women travel to the United States to give birth so that their child can acquire all the privileges of American citizenship. They pay anywhere from $20,000 to sometimes more than $50,000 to brokers who arrange their travel documents, accommodations and hospital stays, often in Florida. While the cost is high, their children will be rewarded with opportunities and travel advantages not available to their Russian countrymen. The parents themselves may benefit someday as well. And the decidedly un-Russian climate in South Florida and the posh treatment they receive in the maternity wards...

China chemical plant blast kills 47, injures hundreds more

Mar 22, 2019

BEIJING — A massive explosion at a chemical plant in eastern China with a long record of safety violations has killed at least 47 people and injured hundreds of others, 90 of them seriously. Thursday's blast in an industrial park in the city of Yancheng, north of Shanghai, was one of China's worst industrial accidents in recent years. State-run television showed crushed cars, blown out windows and workers leaving the factory with bloodied heads. Schools were closed and nearly 1,000 residents were moved to safety as a precaution against leaks and additional explosions, the city government said in a statement...

Asian stocks mixed on doubts over US-China trade deal

Mar 22, 2019

SINGAPORE — Asian markets were mixed on Friday as caution set in ahead of U.S.-China trade talks in Beijing next week. The Shanghai Composite index was 0.1 percent lower at 3,097.81 while the Kospi in South Korea rose 0.1 percent to 2,186.95. Australia's S&P ASX 200 gained 0.5 percent to 6,195.20. Hong Kong's Hang Seng lost 0.4 percent to 28,952.22. Shares rose in Taiwan and Thailand but fell in Indonesia. Japan's Nikkei 225 index, reopening after a market holiday, edged 0.1 percent higher to 21,627.34, even after a report that inflation slowed slightly in February. The core consumer price index...

Jimmy Carter's new milestone: longest-lived US president

Mar 22, 2019

ATLANTA — Nearly four decades after voters unceremoniously rejected then-President Jimmy Carter's bid for a second term, the 39th president has reached a milestone that electoral math cannot dispute: He is now the longest-living chief executive in American history. Friday is the 172nd day beyond Carter's 94th birthday, exceeding by one day the lifespan of former President George H.W. Bush, who died Nov. 30 at the age of 94 years, 171 days. Both men were born in 1924: Bush on June 12, Carter on Oct. 1. It's yet another post-presidency distinction for Carter, whose legacy since leaving office has long...

Iditarod musher discounts critics after dogs refused to run

Mar 22, 2019

ANCHORAGE, Alaska — The Iditarod musher who was hours ahead in the Alaska wilderness race when his dogs refused to keep running dismissed critics who say he ran them too hard and chalked it up to a bad memory that spooked them. The team stopped last week after Frenchman Nicolas Petit yelled at a dog that was bullying another, but they "did not slow down like a tired team would," he said. It came a year after they got lost in a blizzard near the same spot along the Bering Sea coast — close to the finish line of the...

Weather, 20 December
Houston Weather
+7

High: +11° Low: -2°

Humidity: 83%

Wind: NNE - 7 KPH

Canberra Weather
+27

High: +27° Low: +17°

Humidity: 87%

Wind: W - 20 KPH

Roissy-en-France Weather
+6

High: +6° Low: -5°

Humidity: 87%

Wind: ENE - 7 KPH

Florence Weather
+9

High: +9° Low: +6°

Humidity: 97%

Wind: ENE - 17 KPH

Parga Weather
+7

High: +16° Low: +4°

Humidity: 100%

Wind: SE - 25 KPH